# Braveheart Bio Inc. (BRVE)

Source: https://www.quantisnow.com/company/BRVE
Generated: 2026-11-22T17:15:27.947Z

- Ticker: BRVE
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2026
- SEC CIK: 0002131524
- Website: https://www.braveheart.bio/

## About

Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy ('HCM') and other serious cardiovascular diseases. Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor, that we are developing for the treatment of obstructive HCM and non-obstructive HCM. Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity. BHB-1893 was initially discovered and developed by Jiangsu Hengrui Pharmaceuticals Co in China. We in-licensed BHB-1893 pursuant to an exclusive license agreement with Hengrui.

## Latest BRVE news and filings

- 2026-11-16 21:35 UTC [SEC Schedule 13G] [SEC Form SCHEDULE 13G filed by Braveheart Bio Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-braveheart-bio-inc-6794627)
- 2026-11-16 13:00 UTC [SEC Schedule 13G] [SEC Form SCHEDULE 13G filed by Braveheart Bio Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-braveheart-bio-inc-6792402)
- 2026-11-10 21:06 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Braveheart Bio Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-braveheart-bio-inc-6783953)
- 2026-11-10 21:05 UTC [SEC Form 8-K] [Braveheart Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/braveheart-bio-inc-filed-sec-form-8-k-results-of-operations-6783894)
- 2026-11-10 21:03 UTC [Earnings] [Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/braveheart-bio-reports-third-quarter-2026-financial-results-and-provides-6783774)
- 2026-11-09 12:30 UTC [Conference Announcement] [Braveheart Bio to Participate in the Jefferies Global Healthcare Conference in London](https://www.quantisnow.com/insight/braveheart-bio-to-participate-in-the-jefferies-global-healthcare-conference-6780199)
- 2026-11-09 11:02 UTC [SEC Schedule 13G] [SEC Form SCHEDULE 13G filed by Braveheart Bio Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-braveheart-bio-inc-6779911)
- 2026-11-06 20:17 UTC [SEC Form 8-K] [Braveheart Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/braveheart-bio-inc-filed-sec-form-8-k-regulation-fd-disclosure-6778691)
- 2026-11-06 20:15 UTC [Conference Announcement] [Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026](https://www.quantisnow.com/insight/hengrui-pharma-and-braveheart-bio-present-data-from-52-week-open-label-6778687)
- 2026-11-05 18:14 UTC [SEC Schedule 13G] [SEC Form SCHEDULE 13G filed by Braveheart Bio Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-braveheart-bio-inc-6775475)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/BRVE
- Earnings history: https://www.quantisnow.com/earnings/BRVE
- Dividend history: https://www.quantisnow.com/dividends/BRVE
- Insider transactions: https://www.quantisnow.com/insiders/BRVE
- Options chain: https://www.quantisnow.com/options/BRVE
- SEC 8-K filings only: https://www.quantisnow.com/company/BRVE/8-k
- RSS and alerts for BRVE: https://www.quantisnow.com/docs/rss-feeds.md
